Cell and gene therapies (C>s) are swiftly developing within the biopharmaceutical sector. The expanding C> space is exerting substantial influence on the trajectory of healthcare and the management of genetic disorders. C>s provide a long-awaited solution for patients affected by rare diseases, creating a lasting impact by moving away from the treatment of symptoms to providing life-changing cures. However, despite recent advancements, numerous obstacles need attention to help establish C>s as a feasible and extensively adopted therapeutic choice.
In this article, Dr. Samir Acharya, Dr. Rajiv Vaidya and Cyrill Kellerhals from Andelyn Biosciences discuss the trends in the field of C> and explore the current and future challenges facing C> developers and manufacturers as well as solutions to overcome these challenges.